Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

the safety and

tolerability results of ITMN-191 were excellent.

-- That the trial had achieved its principal goals for viral kinetic

performance, safety and tolerability to advance the program into a

triple combination study with Pegasys(R) and ribavirin.

-- It expected to complete enrollment of the third dose cohort in the

MAD study in January 2008. InterMune announced today that

enrollment of that cohort was completed in late January and that

data from the third cohort are not yet available to the company.

-- InterMune expects to begin a 14-day triple combination study of

ITMN-191 with Pegasys(R) and ribavirin in the second quarter of

2008.

Guidance for 2008 Operating Expenses

InterMune today provided its forward-looking guidance with respect to operating expenses in 2008.

For the year ending December 31, 2008, R&D expense is anticipated to be similar to 2007 in a range of approximately $100 to $110 million, net of development cost reimbursements under the Roche collaboration. G&A expense is anticipated to be in a range of approximately $25 to $30 million.

Key Development Program Milestones

InterMune today noted the upcoming milestones with respect to its key development programs.

CAPACITY Program in IPF:

-- InterMune expects to announce top-line results of its Phase 3 CAPACITY

program in IPF in January of 2009.

ITMN-191 Program in HCV:

-- In conjunction with its partner, Roche, InterMune has decided to

complete a fourth cohort of the Phase 1b multiple-ascending-dose (MAD)

study to further inform the planned 14-day triple therapy study and

potential direct anti-viral combination studies in the future.

Consequently, InterMune has decided to announce results from the first

four cohorts of the Phase lb MAD study
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013  HealthSparq, a trusted provider of ... largest regional health plans, will debut a new ... (AHIP) Institute 2013 conference on June 13.  The ... how health insurance companies across the country are ... marketplace demands for increased healthcare transparency. ...
(Date:5/16/2013)... 2013 Scientists at the Center for Learning ... and the California -based biopharmaceutical company ... therapy for reversing memory decline in mice with Alzheimer,s ... cognitive improvement in advanced stage AD mice. The study ... cognitive decline for advanced stage AD mice, and is ...
(Date:5/16/2013)... 16, 2013 On average, developing a ... one billion dollars. Despite this investment, less than 10% ... high, is your clinical trial design optimally structured to ... outcomes? , Dr. Frederic Sax, Global Head of the ... use of data, information and technology in upfront clinical ...
(Date:5/16/2013)... , May 16, 2013 ... research report is available in its ... Cardiac Biomarkers for Acute Coronary Syndromes ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Acute Coronary Syndromes - APAC Analysis ...
Breaking Biology Technology:HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8
... 28 Thermo Fisher,Scientific Inc. (NYSE: TMO ), the world ... conferences: -- Thomas Weisel Partners Healthcare Conference on Friday, Sept. ... the Four Seasons Hotel, Boston, Mass., -- Bear Stearns 20th ... 2007, at 10:30 a.m. (EST) at The Grand Hyatt Hotel, New ...
... With 3.8 Million Patients Under ... ... Accretive to Medco Shareholders in ... 2008, FRANKLIN LAKES, N.J. and WAKEFIELD, Mass., Aug. 28 ,Medco Health Solutions, ...
... and Preclinical-Stage Compounds ... in Merck KGaA ... drug discovery and development company, announced today that,it will collaborate ... discover new applications for drug candidates. KineMed,s,proprietary pathway-based drug discovery ...
Cached Biology Technology:Thermo Fisher Scientific to Present at Investor Conferences 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 3Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 4Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 5Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 6Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 7KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 2
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
(Date:5/19/2013)... engineered a strain of electricity-producing bacteria that can grow ... carbon dioxide as its sole source of carbon. ... findings at the 113th General Meeting of the American ... of current production solely on hydrogen," says Amit Kumar, ... co-authors are part of the Lovley Lab Group at ...
(Date:5/19/2013)... University of California, Davis have engineered a strain of ... They report their findings today at the 113th ... "In this work, we used synthetic biology approaches to ... and light energy for growth) cyanobacterial metabolism for the ... the lead researcher on the study. He is ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2
... General Hospital (MGH) researchers discovered that the spleen ... that could regenerate the insulin-producing islets of the,pancreas. ... of the,same team now report that these potential ... be present only during the embryonic,development of mammals.,The ...
... bat, yet their evolutionary history is largely unknown because of ... their origins and divergence. , Now, a research team including ... a paper in the Jan. 28 issue of the journal ... fill in many of the gaps. , Springer coauthors the ...
... Contrary to the results of a recent U.S. study, ... infection and a potentially life-threatening form of high blood ... The Journal of Infectious Diseases, now available online. , ... detect human herpesvirus 8 (HHV-8), also known as the ...
Cached Biology News:Spleen may be source of versatile stem cells 2Spleen may be source of versatile stem cells 3Molecular biology fills gaps in knowledge of bat evolution 2Association of herpesvirus with lung disorder questioned 2
... SE flow cytometry system is the superior ... over 25 years, BD cell sorters have ... in leading university, pharmaceutical, and biotechnology research ... the research demands of today, we have ...
... allows real-time observations of cell cultures under ... 64 different strain parameters in addition to ... silicon strain chamber used by the ST-195 ... microscopy. ST-195 can be used with Nikon, ...
... RC DC protein assay reagents package is used ... reducing agents and detergents. The RC DC protein ... reagents sufficient for 500 standard assays: 250 ml ... 250 ml alkaline copper tartrate solution, 2 L ...
... Kit is designed for concentration and ... samples. Proteomics sample analysis is often ... impurities such as buffers, salts and ... interfere with electrophoretic separations or enzymatic ...
Biology Products: